alzhub.org
Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

Research

29,380 Alzheimer's and dementia studies in plain English, each scored out of 100.

Find studies

Showing 451–475 of 566 studies in Lewy body dementia (page 19 of 23) · 29,380 in the whole library · How the 0–100 score works

Download bibliography of the first 500 of these studies, in this order: BibTeX (.bib) · RIS (.ris)

Browse by subject, author or institution

Each number is how many studies that link shows, with your other filters kept.

Other subjects

Authors

Names as each record prints them; the same person can appear under two spellings.

Institutions

From OpenAlex; 14,855 studies have no institution on record and are not counted here.

What “Lewy body dementia” covers

Lewy body dementia — Dementia with Lewy bodies and related conditions: how they differ from Alzheimer's in symptoms, diagnosis and care.

A note on reading research. One study is rarely the final word.

We try to note the size of a study, whether it was in humans or animals, and how early-stage the finding is. If a summary here doesn't make that clear, treat it with extra caution and check the original source.

Reasons for and against presymptomatic genetic testing in frontotemporal dementia: a qualitative study

✓ Peer-reviewed alzhub usefulness score 44 out of 100. Human Genetics 2026-02-16

The majority of individuals at 50% risk of carrying a pathogenic variant causing frontotemporal dementia (FTD) chooses not to undergo presymptomatic genetic testing. 5 key findings →

Participants: 14 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Intermittent fasting reprograms the brain proteome to prevent synaptic degeneration and cognitive impairment in vascular dementia

✓ Peer-reviewed alzhub usefulness score 44 out of 100. Theranostics 2025-07-25

These findings establish IF as a potent modulator of synaptic resilience in VaD, acting through coordinated preservation of synaptic structure, inhibition of inflammatory synapse loss, and metabolic reprogramming. 2 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

The association between plasma and MRI biomarkers in dementia with lewy bodies

✓ Peer-reviewed alzhub usefulness score 44 out of 100. Alzheimer s Research & Therapy 2025-08-22

In DLB, plasma concentrations of GFAP and NfL were associated with MTA, GCA-F, and Fazekas scale; and the Aβ42/40 ratio was associated with PA and Fazekas. 5 key findings →

Participants: 92 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Implication of dopamine transporter and electroencephalography biomarkers in dementia with lewy bodies

✓ Peer-reviewed alzhub usefulness score 44 out of 100. Scientific Reports 2025-10-21

Dopamine transporter (DAT) imaging and electroencephalography (EEG) are recommended biomarkers for diagnosing dementia with Lewy bodies (DLB). 4 key findings →

Participants: 120 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

A hypothesis explaining Alzheimer's disease, Parkinson's disease, and dementia with Lewy bodies overlap

✓ Peer-reviewed alzhub usefulness score 43 out of 100. Alzheimer s & Dementia 2025-06-01

Lewy body-involving diseases (LBD) are commonly associated with Parkinson's disease (PD) featuring voluntary movement inhibition, due to dopaminergic neuron dysfunction in the substantia nigra. 1 key finding →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

A next-generation HDAC6 inhibitor for amyotrophic lateral sclerosis and frontotemporal dementia

✓ Peer-reviewed alzhub usefulness score 43 out of 100. Brain 2025-10-07

We present the pharmacological properties of EKZ-438, which demonstrate high selectivity for HDAC6 (>8500-fold selectivity for HDAC6 versus all other HDAC6 paralogues), low nanomolar potency (12 nM) for HDAC6, and importantly, CNS-penetrance (unbound brain-to-plasma partition coefficient [Kp,uu,brain] ≥ 0.55) and high oral bioavailability (fraction of dose absorbed [F%] = 70). 3 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Examining neuropsychiatric symptoms and functional decline in behavioral variant frontotemporal dementia

✓ Peer-reviewed alzhub usefulness score 43 out of 100. International Review of Psychiatry 2025-10-31

Impairments in transactions (47%) and verbal communication (44%) were common at baseline, while impairments in self-care and incontinence ( 40%). 5 key findings →

Participants: 219 Evidence: low

Full summary, score breakdown and related studies → Original source Full text may need a subscription

Genome‐wide association analysis identifies APOE as a mitophagy modifier in Lewy body disease

✓ Peer-reviewed alzhub usefulness score 43 out of 100. Alzheimer s & Dementia 2025-04-01

We identified a significant genome-wide association with p-S65-Ub for rs429358 (apolipoprotein E ε4 [APOE4]) and a suggestive association for rs6480922 (ZMIZ1). 5 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Lewy Bodies Are Not Associated With Neuronal or Synaptic Loss in Dementia With Lewy Bodies

✓ Peer-reviewed alzhub usefulness score 43 out of 100. Neuropathology and Applied Neurobiology 2026-06-01

Across both regions, no evidence of reduced total neuronal density was observed, but a modest reduction in parvalbumin interneurons was observed in the cingulate gyrus, and there were only modest reductions in some synaptic markers in DLB. 4 key findings →

Participants: 20 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Retinal biomarkers for the risk of Alzheimer’s disease and frontotemporal dementia

✓ Peer-reviewed alzhub usefulness score 43 out of 100. Frontiers in Aging Neuroscience 2025-01-10

Our findings provide preliminary empirical support for a relationship between prodromal changes in retinal layers and a higher risk of AD or FTD, suggesting that macular OCT may serve as a non-invasive, sensitive biomarker of high-risk years before the onset of dementia. 3 key findings →

Participants: 148 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Plasma lipidome dysregulation in frontotemporal dementia reveals shared, genotype‐specific, and severity‐linked alterations

✓ Peer-reviewed alzhub usefulness score 43 out of 100. Alzheimer s & Dementia 2025-09-01

FTD subjects exhibited increased plasma levels of gangliosides (GM3(d18:1_16:0), GM3(d18:1_24:1)), ceramide Cer(d18:1_23:0), and select polyunsaturated triacylglycerols. 5 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Accuracy of clinical diagnosis in parkinsonism--a prospective study

✓ Peer-reviewed alzhub usefulness score 42 out of 100. The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques 1991-08-01

Clinical diagnosis of Parkinson's syndrome (PS) is reasonably easy in most cases but the distinction between different variants of PS may be difficult in early cases. 5 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

The role of autophagy in the pathogenesis and treatment of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD)

✓ Peer-reviewed alzhub usefulness score 42 out of 100. Autophagy Reports 2025-03-20

Amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) represent two extremes of a neurodegenerative disease spectrum characterised by overlapping genetic, clinical, and neuropathological features. 5 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

A role for astrocytic miR-129-5p in frontotemporal dementia

✓ Peer-reviewed alzhub usefulness score 42 out of 100. Translational Psychiatry 2025-04-11

Frontotemporal dementia is a debilitating neurodegenerative disorder characterized by frontal and temporal lobe degeneration, resulting in behavioral changes, language difficulties, and cognitive decline. 2 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Tracer kinetic model detecting heterogeneous blood–brain barrier permeability to water and contrast agent in Alzheimer's disease and dementia with Lewy bodies

✓ Peer-reviewed alzhub usefulness score 42 out of 100. Alzheimer s & Dementia 2025-02-01

AD patients exhibited a significant reduction in the water exchange rates across the BBB, whereas DLB patients showed a significant increase in BBB permeability to contrast agent. 5 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

↑ Change the filters

Where “Free full text” comes from

Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read

How the 0–100 score works — and why some entries are capped

This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.

  • Journal tier up to 10 pts
  • Journal's citation record up to 4 pts
  • Study design up to 12 pts
  • Strength of evidence up to 5 pts
  • Peer-review validation up to 10 pts
  • How recent up to 5 pts
  • Sample size up to 4 pts
  • Effect reported up to 3 pts
  • Studied in people up to 3 pts
  • Randomised / blinded up to 2 pts
  • Times cited up to 7 pts
  • Citations per year up to 5 pts
  • Impact for its field and year up to 6 pts
  • Cited by studies here up to 6 pts
  • Still being cited up to 4 pts
  • Senior author's track record up to 4 pts
  • Institution's track record up to 3 pts
  • Multi-centre collaboration up to 3 pts
  • Indexed in PubMed up to 2 pts
  • Free to read up to 2 pts

Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.

Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.

We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.

The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.

See the whole rubric drawn out → — four charts covering all 29,380 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.

What this library is — and isn't

This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 29,380 records, built mostly from automated pulls of Europe PMC (63.3% of the library) and OpenAlex (17.3%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.

1,037 records (3.5% of the library) are not peer-reviewed — 964 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.

See the full, machine-readable breakdown of this library's coverage →

Newest studies, as a dated timeline →    Atom feed